Arcutis Biotherapeutics, Inc.
ARQT
$20.69
-$0.55-2.59%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 98.08% | 123.41% | 183.56% | 250.33% | 335.28% |
| Total Other Revenue | -50.00% | -86.67% | -85.71% | -93.10% | -93.15% |
| Total Revenue | 95.29% | 91.34% | 129.21% | 99.50% | 100.03% |
| Cost of Revenue | 52.41% | 91.84% | 120.55% | 183.11% | 231.13% |
| Gross Profit | 100.93% | 91.29% | 130.22% | 92.54% | 90.14% |
| SG&A Expenses | 19.29% | 19.69% | 14.84% | 19.29% | 21.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.43% | 19.50% | 11.08% | 12.02% | 10.33% |
| Operating Income | 102.65% | 90.48% | 78.98% | 52.25% | 38.25% |
| Income Before Tax | 98.92% | 89.26% | 77.82% | 52.75% | 39.68% |
| Income Tax Expenses | 63.62% | 80.99% | 193.41% | -72.00% | -82.15% |
| Earnings from Continuing Operations | 98.17% | 88.47% | 77.33% | 53.07% | 40.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 98.17% | 88.47% | 77.33% | 53.07% | 40.34% |
| EBIT | 102.65% | 90.48% | 78.98% | 52.25% | 38.25% |
| EBITDA | 104.55% | 93.90% | 81.11% | 54.73% | 40.12% |
| EPS Basic | 98.21% | 88.80% | 80.35% | 65.90% | 64.22% |
| Normalized Basic EPS | 98.95% | 89.55% | 80.77% | 65.42% | 63.73% |
| EPS Diluted | 97.12% | 87.83% | 80.33% | 65.89% | 64.20% |
| Normalized Diluted EPS | 97.98% | 88.68% | 80.63% | 65.42% | 63.73% |
| Average Basic Shares Outstanding | 2.71% | 5.20% | 12.00% | 29.17% | 52.62% |
| Average Diluted Shares Outstanding | 5.24% | 7.81% | 13.16% | 29.17% | 52.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |